Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CV Sciences, Inc.CVSI · Entity 8316 | Director | June 02, 2021 | June 03, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CV Sciences, Inc.
Report date June 02, 2021 · Filed June 03, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.39 · Expires 2031-06-01 | Direct | 275,000 |
Reported balance
After 2021-06-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-02 · Grant · Acquired 275,000 · Balance 275,000 F1: The option is durational-based. All 275,000 option shares vest and become exercisable on April 15, 2022, provided, that there has not been a termination of service as of such date. In no event will any unvested portion of the option vest or become exercisable for any additional option shares after a termination of service. |
Filing footnotes · ownership attribution and instrument terms
F1: The option is durational-based. All 275,000 option shares vest and become exercisable on April 15, 2022, provided, that there has not been a termination of service as of such date. In no event will any unvested portion of the option vest or become exercisable for any additional option shares after a termination of service.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Mylan II B.V.
Report date June 22, 2017 · Filed June 23, 2017
Section 16 reporting ended · disclosed 2017-06-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 29,256 |
Reported balance
After 2017-06-22 transaction · row 1
1 source rowRow 1 · 2017-06-22 · Exercise / conversion · Acquired 3,653 · Balance 29,256 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2017-06-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-06-22 · Exercise / conversion · Disposed 3,653 · Balance 0 F1: Each restricted stock unit ("RSU") represents the right to receive one ordinary share of Mylan N.V. These RSUs vested in full on June 22, 2017 in connection with the conclusion of Dr. Maroon's service as a director on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents the right to receive one ordinary share of Mylan N.V. These RSUs vested in full on June 22, 2017 in connection with the conclusion of Dr. Maroon's service as a director on such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 02, 2021 Filed Jun 3, 2021 17:00 UTC | CV Sciences, Inc. CVSI · Entity 8316 | GrantStock Option (right to buy) · Derivative | 275,000 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001510964-21-000038 · wf-form4_162275399709514.xml · derivative · entry 1 MAROON JOSEPH C MD · CIK 0001221600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2031-06-01 F1 · derivative.exercise_date: The option is durational-based. All 275,000 option shares vest and become exercisable on April 15, 2022, provided, that there has not been a termination of service as of such date. In no event will any unvested portion of the option vest or become exercisable for any additional option shares after a termination of service. Read SEC document |
| May 21, 2021 Filed May 24, 2021 16:59 UTC | CV Sciences, Inc. CVSI · Entity 8316 | PurchaseCommon Stock | 50,000 | $0.38 | $19,000.00 |
DisclosureSEC source: 0001510964-21-000030 · wf-form4_162188994877451.xml · nonDerivative · entry 1 MAROON JOSEPH C MD · CIK 0001221600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 791,116 F1 · price: The shares were purchased in multiple transactions, each at a price of $0.38 per share. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 20:48 UTC | CV Sciences, Inc. CVSI · Entity 8316 | GrantCommon Stock · Derivative | 190,000 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001510964-20-000054 · wf-form4_159252769877664.xml · derivative · entry 1 MAROON JOSEPH C MD · CIK 0001221600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,000 Underlying: Common Stock · 190,000 shares Expires 2030-06-15 F1 · derivative.exercise_date: The option is durational-based. 40,000 option shares vested on the date of grant and the remaining 150,000 option shares vest and become exercisable on June 16, 2021, provided, however, that there has not been a termination of service as of such date. In no event will the option become exercisable for any additional option shares after a termination of service. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 18:25 UTC | CV Sciences, Inc. CVSI · Entity 8316 | PurchaseCommon Stock | 26,000 | $0.94 | $24,440.00 |
DisclosureSEC source: 0001510964-20-000002 · wf-form4_158111791665586.xml · nonDerivative · entry 1 MAROON JOSEPH C MD · CIK 0001221600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 741,116 F1 · price: These shares were purchased in multiple transactions at price of $0.94 per share. F2 · price: The reporting person undertakes to provide CV Sciences, Inc., any security holder of CV Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, the full information regarding the number of shares purchased at each seperate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| December 11, 2019 Filed Dec 23, 2019 19:15 UTC | CV Sciences, Inc. CVSI · Entity 8316 | PurchaseCommon Stock | 46,725 | $1.09 | $50,930.25 |
DisclosureSEC source: 0001510964-19-000079 · wf-form4_157714651123513.xml · nonDerivative · entry 2 MAROON JOSEPH C MD · CIK 0001221600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 715,116 F2 · price: The reporting person undertakes to provide CV Sciences, Inc., any security holder of CV Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, the full information regarding the number of shares purchased at each seperate price within the ranges set forth in footnotes (1) and (2) to this Form 4. F3 · price: The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.07 to $1.09 per share, inclusive. Read SEC document |
| December 05, 2019 Filed Dec 23, 2019 19:15 UTC | CV Sciences, Inc. CVSI · Entity 8316 | PurchaseCommon Stock | 25,000 | $0.98 | $24,500.00 |
DisclosureSEC source: 0001510964-19-000079 · wf-form4_157714651123513.xml · nonDerivative · entry 1 MAROON JOSEPH C MD · CIK 0001221600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 668,391 F1 · price: These shares were purchased in multiple transactions at price of $0.98 per share. F2 · price: The reporting person undertakes to provide CV Sciences, Inc., any security holder of CV Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, the full information regarding the number of shares purchased at each seperate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 19:04 UTC | Mylan II B.V. MYL · Entity 16217 | Exercise / conversionRestricted Stock Units · Derivative | 3,653 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-017148 · doc4.xml · derivative · entry 2 MAROON JOSEPH C MD · CIK 0001221600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,653 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Each restricted stock unit ("RSU") represents the right to receive one ordinary share of Mylan N.V. These RSUs vested in full on June 22, 2017 in connection with the conclusion of Dr. Maroon's service as a director on such date. F1 · derivative.expiration_date: Each restricted stock unit ("RSU") represents the right to receive one ordinary share of Mylan N.V. These RSUs vested in full on June 22, 2017 in connection with the conclusion of Dr. Maroon's service as a director on such date. Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 19:04 UTC | Mylan II B.V. MYL · Entity 16217 | Exercise / conversionOrdinary Shares | 3,653 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-017148 · doc4.xml · nonDerivative · entry 1 MAROON JOSEPH C MD · CIK 0001221600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,256 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2017 Filed Mar 7, 2017 19:17 UTC | Mylan II B.V. MYL · Entity 16217 | GrantRestricted Stock Units · Derivative | 3,653 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-006737 · doc4.xml · derivative · entry 2 MAROON JOSEPH C MD · CIK 0001221600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,653 Underlying: Ordinary Shares · 3,653 shares Expires not disclosed F2 · derivative.exercise_date: Each restricted stock unit (RSU) represents the right to receive one ordinary share of Mylan N.V. These RSUs will vest in full on March 3, 2018. F2 · derivative.expiration_date: Each restricted stock unit (RSU) represents the right to receive one ordinary share of Mylan N.V. These RSUs will vest in full on March 3, 2018. Read SEC document |
| March 03, 2017 Filed Mar 7, 2017 19:17 UTC | Mylan II B.V. MYL · Entity 16217 | GrantNon-Employee Director Stock Option - Right to Buy · Derivative | 2,928 | $0.00 Strike: $45.18 | $0.00 |
DisclosureSEC source: 0000899243-17-006737 · doc4.xml · derivative · entry 1 MAROON JOSEPH C MD · CIK 0001221600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,928 Underlying: Ordinary Shares · 2,928 shares Expires 2027-03-03 F1 · derivative.exercise_date: These options will vest in full on March 3, 2018 and expire on March 3, 2027. Read SEC document |
| February 17, 2017 Filed Feb 21, 2017 19:03 UTC | Mylan II B.V. MYL · Entity 16217 | Exercise / conversionRestricted Stock Units · Derivative | 3,567 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-004827 · doc4.xml · derivative · entry 2 MAROON JOSEPH C MD · CIK 0001221600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,567 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Each restricted stock unit (RSU) represents the right to receive one ordinary share of Mylan N.V. These RSUs vested in full on February 17, 2017. F1 · derivative.expiration_date: Each restricted stock unit (RSU) represents the right to receive one ordinary share of Mylan N.V. These RSUs vested in full on February 17, 2017. Read SEC document |
| February 17, 2017 Filed Feb 21, 2017 19:03 UTC | Mylan II B.V. MYL · Entity 16217 | Exercise / conversionOrdinary Shares | 3,567 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-004827 · doc4.xml · nonDerivative · entry 1 MAROON JOSEPH C MD · CIK 0001221600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,603 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.